ImmuCell expects to complete a $3.5 million freeze-drying capacity investment in the first half of 2027.
The company plans a $4.5 million investment in colostrum processing capacity, expected to take six months.
ImmuCell expects to triple capacity and improve product economics over the next 18 months.
Quarterly results and drivers
Animal health biologics firm's Q2 revenue rose 11.5% yr/yr to $7.2 million.
Q2 net income increased to $1.8 million, aided by a $2 million legal settlement.
Revenue growth was driven by higher distributor out-the-door volume and price realization across sales territories and products.
Q2 gross margin declined due to lower manufacturing volumes, costs from a discontinued development program, and scrap from a quality issue with purchased material.
ICCC•
